Clinical trial NCT04662840: Geniculate Nerve Ablation vs Geniculate Artery Embolization vs Sham for Knee Osteoarthritic Pain
Official title: Prospective Blinded Study Looking at Geniculate Nerve Ablation of the Knee Versus Hyperemic Geniculate Artery Embolization Versus Sham Procedure for Pain Control in Patients With Knee Osteoarthritis
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE4
Conditions: Osteoarthritis, Knee
Keywords: artery embolization
nerve ablation
Lead sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre
Sponsor class: OTHER
First posted: 2020-12-10
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: three-arm prospective double-blinded randomized comparative trial
Primary purpose: TREATMENT

Brief summary: This is a three-arm prospective double-blinded randomized comparative trial aimed at comparing results regarding knee pain improvement in patients with osteoarthritis (OA) of the knee awaiting total knee arthroplasty (TKA) by either a sham procedure, a geniculate artery embolization procedure or a geniculate nerve ablation procedure. Experienced interventional radiologists and anesthetists at the McGill University Health Centre (MUHC) and study affiliated centers will carry out all interventions. 72 consecutive subjects meeting the eligibility criteria, considered for knee replacement in the future. Patients will be randomized to receive either the embolization procedure, the nerve ablation procedure or a sham procedure. Monitoring of pain will be recorded using visual analog scales, pain medication use, and Western Ontario and McMaster Universities Arthritis Index (WOMAC) and osteoarthritis knee and hip quality of life questionnaire (OAKHQOL) questionnaires over a period of 1 year post-treatment or up to the time of surgery. Pain and recovery post surgery will be monitored as well in patients who do get the Total Knee Arthroplasty (TKA) before the 1 year mark.

Detailed description: This is a three-arm prospective double-blinded randomized comparative trial. Experienced interventional radiologists and anesthetists at the MUHC and study affiliated centers will carry out all interventions.

* 72 consecutive subjects meeting the eligibility criteria, considered for knee replacement in the future.
* Patients will be referred for consideration for the study by specialized arthroplasty orthopedic surgeons from their osteoarthritis clinic at St-Mary's hospital.
* Prospective patients interested will be referred to the interventional radiology clinic at the MUHC for discussion of the procedures and of the study and recruitment.
* Consent will be obtained from all patients.
* Patients who accept to participate and fit the criteria will be randomized to receive either the embolization procedure, the nerve ablation procedure or a sham procedure. They will fill out the Western Ontario and McMaster Universities Arthritis Index (WOMAC) and osteoarthritis knee and hip quality of life questionnaire (OAKHQOL) questionnaires as well the Visual Analog Scale (VAS) for pain which will serve as baseline.
* They will then be contacted by the appropriate service to schedule the procedure.
* All embolization or nerve ablation procedures will be performed by either a qualified interventional radiologist or anesthetist.

Patients will be informed that they will not know which procedure they will receive. A barrier will be placed to shield them from visualizing the procedure and, for both procedures and sham procedure, skin freezing, and post-procedural bandages will be applied to the groin and in the skin around the knee. The patients will be informed that the procedures can take similar time between 15 minutes and 1 hr and that timing is variable between patients. They will also be informed that pain sensation around the knee can be similar between procedures. For all procedures, a written scenario (words and manipulations of the skin) will be followed such that all patients have the impression they are getting the same thing despite some having only the sham, others the embolization, and others the denervation. At the end of all procedures, patients will be transferred to the recovery room as per routine for interventional radiology procedures. Recovery room nurses will not know which of the procedures the patient had. They will be informed to look out for possible complications from either procedure. Patients will be informed that they must remain with their legs still for 3hrs after the procedure to prevent bleeding from the possible puncture in the artery that is necessary for the embolization procedure. No procedure specific technical discussion regarding the procedure will occur during the procedures to suggest what was done, only the common scenario will be followed. All this will be done in an attempt to blind the patient as much as possible. Blinding will be lifted for once the patient has completed the study. There is a final questionnaire to be filled out by the patient and physician at which point the patient will be informed of what procedure they received.

* The patients will be offered IV analgesia using midazolam and fentanyl during the procedure at regular intervals and the patients will be left to decide if they think it is necessary or not.
* Analgesics will be provided as per set orders during the recovery period in the post-procedural recovery room. Pain scales and medications provided are routinely registered in Post-Anesthesia Care Unit (PACU) documents and this data will be collected
* The patient will be discharged home with standard prescriptions for 2-3 days of post-procedural home analgesics and then will restart their routine pain control regimen they have been using.
* After the procedure, while at home, the patient will fill out paper or on-line confidential surveys (only study number on the survey, no patient identifying information) of routine medications used, WOMAC questionnaires and a VAS at regular interval (1d, 1wk, 2wks, 1m, 2m, 3m, 6m, 9m, 12m and if the patient has surgery at 1wk, 2wk, 1m, 2m, and 3m post-surgery). In addition, the OAKHQOL questionnaire will be filled out at 1m, 6m, and 12m and if the patient has surgery a 3m after surgery. The patients will be contacted by phone to make sure they remember to fill these out at the correct intervals. If they have chosen to use the paper forms, they will be collected in a pre-stamped envelope to send back to us at the 12m mark.
* A patient will be considered to have completed the study after 12m without knee surgery or 3m after a knee replacement surgery, whichever occurs first.
* Data will be gathered, stored, and analyzed.
* Data collected will include demographics, relevant medical history, vital signs, which procedure was performed, as well as the use of IV and oral analgesics, visual analog pain scores (VAS), WOMAC, and OAKHQOL questionnaires, X-rays performed during routine follow-ups at the orthopedic surgery clinic will be graded as per International Knee Documentation Committee (IKDC) grading system.
* Other than the initial visit aimed at getting consent and randomizing the patients and the procedures themselves, any research specific patient encounters scheduled in this study will be done by phone, unless the patient requests otherwise.

Eligibility criteria: Inclusion Criteria:

1. Patients diagnosed with knee osteoarthritis awaiting knee replacement surgery (expected to be more than a 3m waiting time) presenting with knee pain that patients consider unsatisfactorily managed by routine oral pain medications or cannot tolerate such medications.
2. Patients 18 y.o. or older

Exclusion Criteria:

1. Patients who are expected to have TKA surgery within 3 months.
2. Patients in whom the anatomy prevents either procedure

   * Vascular anatomy that prevents vascular access such as occluded vasculature to the leg
   * Skin or deep infection that would prevent placement of needles
3. Suspected concomitant infected knee joint or other signs of infections such as fever
4. Patients with uncorrectable abnormal coagulation status (INR \>1.5 and plt \< 50,000 without use of anticoagulation agents)
5. Patients who have known severe allergy to the anesthetic agent or contrast
6. Patients with pre-existing conditions, which, in the opinion of the investigator, interfere with the conduct of the study
7. Patients who are uncooperative, cannot follow instructions, or who are unlikely to comply with follow-up appointments or fill-out the post-procedural pain questionnaires
8. Patients with mental state that may preclude completion of the study procedure or be unable to provide informed consent

Primary outcomes:
measure: Changes in knee pain post geniculate artery embolization versus nerve ablation vs sham
timeFrame: 1 year
measure: Changes in knee pain/functionality in geniculate artery embolization versus nerve ablation vs sham
timeFrame: 1 year
measure: Changes in pain medication use in geniculate artery embolization versus nerve ablation vs sham
timeFrame: 1 year
Secondary outcomes:
measure: Comparison of incidence of complications in geniculate artery embolization vs geniculate nerve ablation vs sham
timeFrame: 1 year
measure: Changes in VAS pain scores after TKA in geniculate artery embolization vs geniculate nerve ablation vs sham
timeFrame: 3 months post-surgery
measure: Changes in quality of life in geniculate artery embolization versus nerve ablation vs sham
timeFrame: 1 year
Other outcomes:
Locations:
city: Montreal
country: Canada
facility: McGill University Health Centre
state: Quebec
city: Montréal
country: Canada
facility: McGill University Health Centre
state: Quebec
Study officials:
References: